Abstract
Objective
To study the protective mechanism of Chinese medicine Suxiao Jiuxin Pills (速效救心丸, SXJ) on myocardial ischemia and reperfusion (I/R) injury.
Methods
Mouse myocardial I/R injury model was created by 30-min coronary artery occlusion followed by 24-h reperfusion, the mice were then divided into the sham group (n=7), the I/R group (n=13), the tirofiban group (TIR, positive drug treatment, n=9), and the SXJ group (n=11). Infarct size (IS), risk region (RR), and left ventricle (LV) were analyzed with double staining methods. In addition, H9C2 rat cardiomyocytes were cultured with Na2S2O4 to simulate I/R in vitro. The phosphorylation of extracellular regulated protein kinases1/2 (ERK1/2), protein kinase B (AKT), glycogen synthase kinase-3β (GSK3β), and protein expression of GATA4 in nucleus were detected with Western blot assay.
Results
The ratio of IS/RR in SXJ and TIR groups were lower than that in I/R group (SXJ, 22.4% ±6.6%; TIR, 20.8%±3.3%; vs. I/R, 35.4%±3.7%, P<0.05, respectively). In vitro experiments showed that SXJ increased the Na2S2O4-enhanced phosphorylation of AKT/GSK3β and nuclear expression of GATA4.
Conclusion
SXJ prevents myocardial I/R injury in mice by activating AKT/GSK3β and GATA4 signaling pathways.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Lakota J. Molecular mechanism of ischemia-reperfusion injury after myocardial infarction and its possible targeted treatment. Int J Cardiol 2016;220:571–572.
Guo Y, Wu WJ, Qiu Y, Tang XL, Yang Z, Bolli R. Demonstration of an early and a late phase of ischemic preconditioning in mice. Am J Physiol 1998;275:H1375–87.
Lejay A, Fang F, John R, Van JA, Barr M, Thaveau F, et al. Ischemia reperfusion injury, ischemic conditioning and diabetes mellitus. J Mol Cell Cardiol 2016;91:11–22.
Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China. Beijing: Chinese Medical Science and Technology Press; 2015:1341.
Duan X, Zhou L, Wu T, Liu G, Qiao J, Wei J, et al. Chinese herbal medicine Suxiao Jiuxin Wan for angina pectoris. Cochrane Database Syst Rev 2008;23:CD004473.
Lu Z, Zhang Y, Zhuang P, Zhang J, Zhou H, Zhang M, et al. Protective effect of Suxiao Jiuxin Pill, a traditional Chinese medicine, against acute myocardial ischemia in dogs. BMC Complement Altern Med 2015;15:373–380.
Guo QX, Zhang J, Li YQ, Zhang GF. Study on anti-atherosclerotic effect of Suxiao Jiuxin Pill and its mechanism. Afr J Tradit Complement Altern Med 2013;11:97–102.
Bai XY, Zhang P, Yang Q, Liu XC, Wang J, Tong YL, et al. Suxiao Jiuxin Pill induces potent relaxation and inhibition on contraction in human artery and the mechanism. Evid Based Complement Altern Med 2014;2014:956924.
Qi J, Yu J, Wang L, Guo L, Ma S, Huang D, et al. Tongguan Capsule protects against myocardial ischemia and reperfusion injury in mice. Evid Based Complement Altern Med 2013;2013:159237.
Qi JY, Wang L, Gu DS, Guo LH, Zhu W, Zhang MZ. Protect effects of Danlou Tablet against murine myocardial ischemia and reperfusion injury in vivo. Chin J Integr Med 2018;24:613–620.
Qi JY, Yu J, Huang DH, Guo LH, Wang L, Huang X, et al. Salvianolate reduces murine myocardial ischemia and reperfusion injury via ERK1/2 signaling pathways in vivo. Chin J Integr Med 2017;23:40–47.
Jiang YR, Miao Y, Yang L, Xue M, Guo CY, Ma XJ, et al. Effect of Chinese herbal drug-containing serum for activating-blood and dispelling-toxin on ox-LDL-induced inflammatory factors’ expression in endothelial cells. Chin J Integr Med 2012;18:30–33.
Liao WQ, Wang SY, Han CD, Zhang YY. 14-3-3 Proteins regulate glycogen synthase 3β phosphorylation and inhibit cardiomyocyte hypertrophy. FEBS Journal 2005;272:1845–1854.
Das A, Xi L, Kukreja RC. Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J Biol Chem 2008;283:29572–29585.
Wang J, Ji SY, Liu SZ, Jing R, Lou WJ. Cardioprotective effect of breviscapine: inhibition of apoptosis in H9C2 cardiomyocytes via the PI3K/AKT/eNOS pathway following simulated ischemia/reperfusion injury. Pharmazie 2015;70:593–597.
Meganathan K, Sotiriadou I, Natarajan K, Hescheler J, Sachinidis A. Signaling molecules, transcription growth factors and other regulators revealed from in vivo and in vitro models for the regulation of cardiac development. Int J Cardiol 2015;183:117–128.
Xu X, Zhang L, Liang J. Rosuvastatin prevents pressure overload-induced myocardial hypertrophy via inactivation of the AKT, ERK1/2 and GATA4 signaling pathways in rats. Mol Med Rep 2013;8:385–392.
Liang Q, De Windt, LJ, Witt SA, Kimball TR, Markham BE, Molkentin JD. The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo. J Biol Chem 2001;276:30245–30253.
Rysä J, Tenhunen O, Serpi R, Soini Y, Nemer M, Leskinen H, et al. GATA-4 is an angiogenic survival factor of the infarcted heart. Circ Heart Fail 2010;3:440–450.
Kim Y, Ma AG, Kitta K, Fitch SN, Ikeda T, Ihara Y, et al. Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis. Mol Pharmacol 2003;63:368–377.
Author information
Authors and Affiliations
Contributions
Zhang MZ and Qi JY conceived and designed the experiments, Tan YF and Yu J performed the experiments, Tan YF and Yu J analyzed the data, Pan WJ contributed reagents/materials/analysis tools. Zhang MZ and Qi JY wrote the manuscript. All authors read and approved the final version of the manuscript.
Corresponding author
Additional information
Conflict of Interest
The authors declare no competing financial interests.
Supported by the National Natural Science Foundation of China (No. 81473471 and No. 81603429) and Foundation of Guangdong Hospital of Chinese Medicine (No. YK2013B2N11, No. YN2014ZH01, No. YN2014ZHR203, and No. YN2016QJ19).
Electronic Supplementary Material
Rights and permissions
About this article
Cite this article
Tan, Yf., Yu, J., Pan, Wj. et al. Protective Mechanisms of Suxiao Jiuxin Pills (速效救心丸) on Myocardial Ischemia-Reperfusion Injury in vivo and in vitro. Chin. J. Integr. Med. 26, 583–590 (2020). https://doi.org/10.1007/s11655-020-2726-2
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11655-020-2726-2